TriGemX Bio announces $246 million SPAC merger

Full story: https://grafa.com/en/news/united-states/trigemx-bio-tcgx-246-million-spac-merger

TriGemX Bio and TCGX Acquisition Corp. signed a definitive business combination agreement that would take the migraine drug developer public on Nasdaq under the proposed ticker TGEM.
The transaction is expected to generate approximately $246 million in gross proceeds, including a $160 million private investment in public equity (PIPE) and approximately $86 million held in the SPAC's trust account.
TriGemX expects the proceeds to support Phase 3 trials of elismetrep, additional migraine prevention research and preparations for a potential U.S. commercial launch.

TCGX Acquisition Corp. (NASDAQ:TCGX) agreed to merge with TriGemX Bio in a transaction expected to generate approximately $246 million in gross proceeds.

The proposed financing includes a $160 million PIPE and $86 million in trust funds, although shareholder redemptions could reduce available proceeds.

The PIPE will issue shares at $10 each, with investors including Viking Global, BVF Partners, ADAR1 Capital and Samsara BioCapital.

The companies expect to complete the merger in Q1 2027, subject to shareholder approvals and closing conditions.

The combined company is expected to trade as TGEM with an approximately $600 million equity valuation, assuming no shareholder redemptions.

TriGemX is developing elismetrep for acute migraine treatment and prevention, while TCGX is a healthcare-focused acquisition company that completed its IPO in August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":620356571738336,"tweetId":"620356571738336","gmtCreate":1792484855319,"gmtModify":1792484862182,"author":{"id":4169784042383112,"idStr":"4169784042383112","authorId":4169784042383112,"authorIdStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","vip":2,"userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":258,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/ad125f59423aa1da6954762e0ee9d16c","width":"1920","height":"1080"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/ad125f59423aa1da6954762e0ee9d16c","width":"1920","height":"1080"}],"title":"TriGemX Bio announces $246 million SPAC merger","html":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/ad125f59423aa1da6954762e0ee9d16c\" tg-width=\"1920\" tg-height=\"1080\"></p>\n<p>Full story: https://grafa.com/en/news/united-states/trigemx-bio-tcgx-246-million-spac-merger</p>\n<ul>\n <li>\n  <p>TriGemX Bio and TCGX Acquisition Corp. signed a definitive business combination agreement that would take the migraine drug developer public on Nasdaq under the proposed ticker TGEM.</p></li>\n <li>\n  <p>The transaction is expected to generate approximately $246 million in gross proceeds, including a $160 million private investment in public equity (PIPE) and approximately $86 million held in the SPAC's trust account.</p></li>\n <li>\n  <p>TriGemX expects the proceeds to support Phase 3 trials of elismetrep, additional migraine prevention research and preparations for a potential U.S. commercial launch.</p></li>\n</ul>\n<p style=\"text-align: start;\">TCGX Acquisition Corp. (NASDAQ:TCGX) agreed to merge with TriGemX Bio in a transaction expected to generate approximately $246 million in gross proceeds.</p>\n<p style=\"text-align: start;\">The proposed financing includes a $160 million PIPE and $86 million in trust funds, although shareholder redemptions could reduce available proceeds.</p>\n<p style=\"text-align: start;\">The PIPE will issue shares at $10 each, with investors including Viking Global, BVF Partners, ADAR1 Capital and Samsara BioCapital.</p>\n<p style=\"text-align: start;\">The companies expect to complete the merger in Q1 2027, subject to shareholder approvals and closing conditions.</p>\n<p style=\"text-align: start;\">The combined company is expected to trade as TGEM with an approximately $600 million equity valuation, assuming no shareholder redemptions.</p>\n<p style=\"text-align: start;\">TriGemX is developing elismetrep for acute migraine treatment and prevention, while TCGX is a healthcare-focused acquisition company that completed its IPO in August 2026.</p></body></html>","htmlText":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/ad125f59423aa1da6954762e0ee9d16c\" tg-width=\"1920\" tg-height=\"1080\"></p>\n<p>Full story: https://grafa.com/en/news/united-states/trigemx-bio-tcgx-246-million-spac-merger</p>\n<ul>\n <li>\n  <p>TriGemX Bio and TCGX Acquisition Corp. signed a definitive business combination agreement that would take the migraine drug developer public on Nasdaq under the proposed ticker TGEM.</p></li>\n <li>\n  <p>The transaction is expected to generate approximately $246 million in gross proceeds, including a $160 million private investment in public equity (PIPE) and approximately $86 million held in the SPAC's trust account.</p></li>\n <li>\n  <p>TriGemX expects the proceeds to support Phase 3 trials of elismetrep, additional migraine prevention research and preparations for a potential U.S. commercial launch.</p></li>\n</ul>\n<p style=\"text-align: start;\">TCGX Acquisition Corp. (NASDAQ:TCGX) agreed to merge with TriGemX Bio in a transaction expected to generate approximately $246 million in gross proceeds.</p>\n<p style=\"text-align: start;\">The proposed financing includes a $160 million PIPE and $86 million in trust funds, although shareholder redemptions could reduce available proceeds.</p>\n<p style=\"text-align: start;\">The PIPE will issue shares at $10 each, with investors including Viking Global, BVF Partners, ADAR1 Capital and Samsara BioCapital.</p>\n<p style=\"text-align: start;\">The companies expect to complete the merger in Q1 2027, subject to shareholder approvals and closing conditions.</p>\n<p style=\"text-align: start;\">The combined company is expected to trade as TGEM with an approximately $600 million equity valuation, assuming no shareholder redemptions.</p>\n<p style=\"text-align: start;\">TriGemX is developing elismetrep for acute migraine treatment and prevention, while TCGX is a healthcare-focused acquisition company that completed its IPO in August 2026.</p></body></html>","text":"Full story: https://grafa.com/en/news/united-states/trigemx-bio-tcgx-246-million-spac-merger TriGemX Bio and TCGX Acquisition Corp. signed a definitive business combination agreement that would take the migraine drug developer public on Nasdaq under the proposed ticker TGEM. The transaction is expected to generate approximately $246 million in gross proceeds, including a $160 million private investment in public equity (PIPE) and approximately $86 million held in the SPAC's trust account. TriGemX expects the proceeds to support Phase 3 trials of elismetrep, additional migraine prevention research and preparations for a potential U.S. commercial launch. TCGX Acquisition Corp. (NASDAQ:TCGX) agreed to merge with TriGemX Bio in a transaction expected to generate approximately $246 million in gross proceeds. The proposed financing includes a $160 million PIPE and $86 million in trust funds, although shareholder redemptions could reduce available proceeds. The PIPE will issue shares at $10 each, with investors including Viking Global, BVF Partners, ADAR1 Capital and Samsara BioCapital. The companies expect to complete the merger in Q1 2027, subject to shareholder approvals and closing conditions. The combined company is expected to trade as TGEM with an approximately $600 million equity valuation, assuming no shareholder redemptions. TriGemX is developing elismetrep for acute migraine treatment and prevention, while TCGX is a healthcare-focused acquisition company that completed its IPO in August 2026.","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/620356571738336","repostId":0,"isVote":1,"tweetType":1,"viewCount":14,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1313,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/620356571738336"}